echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > China's first epothilone breast cancer class 1 new drug Utidelone approved for marketing

    China's first epothilone breast cancer class 1 new drug Utidelone approved for marketing

    • Last Update: 2021-03-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Source: Instant Medicine

    On March 12, the website of China National Medical Products Administration (NMPA) showed that Huahao Zhongtian's Class 1 new drug Utidelon obtained the drug approval number.


    .


    Data in 2020 show that the number of new breast cancers reached 2.


    Utidrolone is a genetically engineered epothilone (epothilones) derivative.


    In addition to being used for chemotherapy of advanced breast cancer, Utidelone has also shown anti-tumor activity against common tumors such as lung cancer, liver cancer, bowel cancer and prostate cancer in previous studies, and is resistant to paclitaxel and many other chemotherapeutic drugs.


    It is hoped that this drug can bring new treatment options to breast cancer patients, and it is also expected that it can help improve the lives of more patients in the future.


    Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.


    Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.


    Reference materials:

    [1] On March 12, 2021, the drug approval document pending information is released.


    [1] On March 12, 2021, the drug approval document pending information is released.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.